Business

MOST VIEWED

A collage with two hands about to shake, logos for Johnson & Johnson and Ollin Biosciences, a corporate building, and a syringe and vial
Business

J&J Goes Retina Shopping, Picks Up Ollin Biosciences for Up to US$3.3B

With VEGF and Ang2 in its sights, OLN324 has caught Johnson & Johnson’s eye. Now comes the Phase III test. Johnson & Johnson (New Jersey, United States) is heading for the retina aisle. The company announced that it has signed a definitive agreement to acquire Ollin Biosciences (Texas, United States), and with it OLN324, a...
Appasamy_RUCK thumbnail
Business

Appasamy Acquires RUCK to Take Qube Pro Phaco-Vitrectomy Global

German phaco-vitrectomy know-how meets Indian scale. Can Qube Pro go global with Appasamy behind it?  RUCK has a new owner with a much bigger reach. Appasamy Associates (Chennai, India), a Warburg Pincus-backed manufacturer of intraocular lenses (IOLs) and surgical equipment, has acquired RUCK (Eschweiler, Germany), maker of the Pentasys, Qube and Qube Pro systems for...
Alcon_goes_cellular thumbnail_(1)
Business

Alcon Bets $550 Million on ENCELTO, the Only FDA-Approved MacTel Treatment

Nineteen months after approval, MacTel’s lone therapy trades a biotech for one of eye care’s biggest names.  Alcon (Geneva, Switzerland) has acquired Neurotech Pharmaceuticals (Rhode Island, United States) for $550 million, taking ownership of ENCELTO (revakinagene taroretcel-lwey), the only FDA-approved treatment for macular telangiectasia (MacTel) type 2 .  Announced on October 20, 2026, the acquisition...
Illustration of two hands reaching toward each other, with a checklist and speech bubble representing a leadership change at Bausch + Lomb.
Business

Bausch + Lomb Hands CEO Role to Appio as Saunders Exits

New leadership at Bausch + Lomb comes with a stronger financial outlook.  Bausch + Lomb (Canada) has a new face at the top. Brent Saunders has stepped down as CEO, while Thomas J. Appio took over on an interim basis, effective yesterday, October 12, 2026. The change comes as both Bausch + Lomb and parent...
Four speakers presenting career paths for young ophthalmologists at AAO 2026
Beyond the Clinic

Beyond the Clinic: Four Career Paths for Young Ophthalmologists at AAO 2026

From evaluating therapies at the FDA to building medical devices, earning professional trust, and planning for financial independence, young ophthalmologists explored where a clinical career can lead. Dr. Patricia Buehler (United States) could finish a cataract or LASIK case in about 10 minutes. Blepharoplasty took 30 to 40 minutes, she said. She went on to...
A collage of images Breye Therapeutics logo a hand holding pills an eye and $67.5m
Tech and Pharma

Breye Therapeutics Raises €67.5m to Test an Oral Pill for Early Diabetic Retinopathy

Watch-and-wait has been the NPDR playbook for years. A Danish biotech wants to rewrite it with a pill.  For most patients with early diabetic retinopathy, management still means monitoring and waiting until the disease progresses far enough to warrant injections. Breye Therapeutics (Copenhagen, Denmark) is betting a pill can change that, and investors have put...
Eye care professional holding a tablet beside a hand giving an eye injection, with medication vials against a stylized eye background.
Business

Merck’s Remigromig Matches Ranibizumab in Phase IIb/III DME Trial

Remigromig matches ranibizumab on vision, but safety signals leave a few questions hanging.  Merck’s (Darmstadt, Germany) investigational Wnt pathway agonist remigromig (Restoret) has held its own against ranibizumab in the pivotal Phase IIb/III BRUNELLO trial in diabetic macular edema (DME), though the topline data came with a safety asterisk. At 52 weeks, both remigromig doses...
Six contact lenses float against a warm, softly lit background beside the CooperVision logo.
Business

CooperVision Unveils Global Innovation Hub, Teases Six Contact Lens Advancements

The facility brings research, clinical work and manufacturing closer together as several programs move forward.  U.S.-based CooperVision has given its innovation efforts a new address. The company has opened The Vision Centre, a 9,940-square-meter global innovation hub in Southampton, England, that brings research, clinical expertise, pilot manufacturing and technology teams under one roof.  At the...

No entries were found for this taxonomy term.